EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?

被引：81
作者：
Ke, E-E [1 ,2 ]
Wu, Yi-Long [1 ,2 ]
机构：
[1] Guangdong Acad Med Sci, Guangdong Lung Canc Inst, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangdong Gen Hosp, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China
来源：
TRENDS IN PHARMACOLOGICAL SCIENCES | 2016年 / 37卷 / 11期
关键词：
GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; CIRCULATING TUMOR DNA; PHASE-II TRIAL; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; BRAIN METASTASES; C797S MUTATION; ASIAN PATIENTS;
D O I：
10.1016/j.tips.2016.09.003
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors (TKIs) is highly effective in terms of tumor response rate, survival, and quality of life. However, acquired resistance to EGFR-TKIs is inevitable. Ongoing clinical trials will provide evidence for optimal strategies for patients with EGFR mutant non-small-cell lung cancer (NSCLC) in the near future. Numerous new agents are specifically addressing resistance mechanisms; mature data are related to the T790M mutation and MET pathway activation. Here, we provide a comprehensive review of new perspectives on how to optimize the management of this molecular disease.
引用
收藏
页码：887 / 903
页数：17
相关论文
共 50 条
  • [31] Tumor immune microenvironment of EGFR-mutant non-small-cell lung cancer and its impact on therapeutic efficacy
    Matsumoto, Yoshiya
    Koh, Yasuhiro
    IMMUNOTHERAPY, 2020, 12 (07) : 431 - 438
  • [32] Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
    Kim, Youjin
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    Sun, Jong-Mu
    CANCER RESEARCH AND TREATMENT, 2019, 51 (02): : 502 - 509
  • [33] Clinical Predictors of Response to EGFR Tyrosine Kinase inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Fukihara, Jun
    Watanabe, Naohiro
    Taniguchi, Hiroyuki
    Kondoh, Yasuhiro
    Kimura, Tomoki
    Kataoka, Kensuke
    Matsuda, Toshiaki
    Yokoyama, Toshiki
    Hasegawa, Yoshinori
    ONCOLOGY, 2014, 86 (02) : 86 - 93
  • [34] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Ortiz-Cuaran, Sandra
    Ricciuti, Biagio
    Mezquita, Laura
    Cardona, Andres Felipe
    Recondo, Gonzalo
    CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591
  • [35] Beyond EGFR TKI in EGFR-mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome
    Remon, J.
    Moran, T.
    Reguart, N.
    Majem, M.
    Carcereny, E.
    Lianes, P.
    CANCER TREATMENT REVIEWS, 2014, 40 (06) : 723 - 729
  • [36] Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
    Sequist, L. V.
    Soria, J-C
    Goldman, J. W.
    Wakelee, H. A.
    Gadgeel, S. M.
    Varga, A.
    Papadimitrakopoulou, V.
    Solomon, B. J.
    Oxnard, G. R.
    Dziadziuszko, R.
    Aisner, D. L.
    Doebele, R. C.
    Galasso, C.
    Garon, E. B.
    Heist, R. S.
    Logan, J.
    Neal, J. W.
    Mendenhall, M. A.
    Nichols, S.
    Piotrowska, Z.
    Wozniak, A. J.
    Raponi, M.
    Karlovich, C. A.
    Jaw-Tsai, S.
    Isaacson, J.
    Despain, D.
    Matheny, S. L.
    Rolfe, L.
    Allen, A. R.
    Camidge, D. R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (18) : 1700 - 1709
  • [37] Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis
    Chiang, Chi-Lu
    Lee, Cheng-Chia
    Huang, Hsu-Ching
    Wu, Chia-Hung
    Yeh, Yi-Chen
    Shen, Chia-, I
    Luo, Yung-Hung
    Shiao, Tsu-Hui
    Chang, Han Jhih
    Huang, Yu-Ting
    Chen, Yuh-Min
    Chou, Teh-Ying
    Chiu, Chao-Hua
    TARGETED ONCOLOGY, 2021, 16 (02) : 207 - 214
  • [38] EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Nan, Xueli
    Xie, Chao
    Yu, Xueyan
    Liu, Jie
    ONCOTARGET, 2017, 8 (43) : 75712 - 75726
  • [39] Real-World Data on Prognostic Factors for Overall Survival in EGFR-Mutant Non-Small-Cell Lung Cancer Patients with Brain Metastases
    Yu, Xiaoqing
    Fan, Yun
    JOURNAL OF CANCER, 2019, 10 (15): : 3486 - 3493
  • [40] EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?
    Cansouline, Xavier
    Lipan, Beatrice
    Sizaret, Damien
    Tallet, Anne
    Vandier, Christophe
    Carmier, Delphine
    Legras, Antoine
    CANCERS, 2022, 14 (09)
12345